TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02427022

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CTI
Description: CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CTI
Description: CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.
Study: NCT00708968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOCUS Program
Description: Supportive, educative sessions with patients and spouses.
Study: NCT02447042

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid challenge with crystalloids
Description: Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.
Study: NCT00655122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin sodium
Description: Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
Study: NCT01626755

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sciatic name block
Description: Ultrasound-guided sciatic nerve block.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic name block
Description: Ultrasound-guided sciatic nerve block.
Study: NCT00342628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-rEPA conjugate vaccine for typhoid fever
Description: Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib-TT
Description: Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP
Description: DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP
Description: DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
Study: NCT04378738

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: survey
Description: all people in the cohort
Study: NCT04463797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Square-stepping exercise
Description: The square-stepping exercise is a low-cost indoor program to improve lower extremities fitness and cognitive function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and strengthening
Description: whole-body stretching and upper extremity strengthening
Study: NCT01307176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: The home exercise program uses standard physical therapy exercises that have never been rigorously tested for people with cerebellar ataxia. These include sitting balance exercises (e.g. sitting on a peanut-shaped exercise ball and moving arms or legs), standing balance exercises (e.g. weight shifting, moving arms and legs), and walking exercises (e.g. walking heel-to-toe). The exercises are in a progression, going from less to more challenging. Though the exercises are standard, they are the intervention that we are testing and we will consider them experimental.
Study: NCT06027385

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: molecular-based screening
Description: Test for three mutations in the CTNS gene and one mutation in the SMA1 gene.
Study: NCT00624442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 1.0 mg/kg/h followed by 23 hours at 0.1 mg/kg/h
Study: NCT03054415

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopy
Description: colonic biopsies during endoscopy and anal manometry with barostat and anal endoflip
Study: NCT01074294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPDC-34712
Description: OPDC-34712 tablets, daily, Orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching-placebo tablets, daily, Orally.
Study: NCT02361242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT00864
Description: PXT00864 is a fixed-dose combination of baclofen and acamprosate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT00864
Description: PXT00864 is a fixed-dose combination of baclofen and acamprosate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXT00864
Description: PXT00864 is a fixed-dose combination of baclofen and acamprosate
Study: NCT01074294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching-placebo tablets, daily, Orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching-placebo tablets, daily, Orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stimulant Therapy
Description: Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stimulant Therapy
Description: Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stimulant Therapy
Description: Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stimulant Therapy
Description: Mixed amphetamine salts or Dexmethylphenidate hydrochloride (HCL) or Methylphenidate HCl or Lisdexamfetamine dimesylate as per standard of care.
Study: NCT02831231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xanomeline tartrate
Description: xanomeline tartrate, 75 mg capsule, TID
Study: NCT04569669

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FFR and FFRCT
Description: All the patients will undergo computed coronary tomography angiography to analysis FFRCT . Then FFR will be measured during invasive cardiac catheterization.
Study: NCT04187417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical tetracaine hydrochloride 1%
Description: topical ophthalmologic anesthestic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01773837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: methylphenidate (pill) p.o. 15 to 25 mg daily for six days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (pill) p.o.
Study: NCT02831231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xanomeline tartrate
Description: xanomeline tartrate, 75 mg capsule, TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium chloride
Description: trospium chloride, over encapsulated 20 mg tablet, BID
Study: NCT01250769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Toothbrush
Description: A standard size manual toothbrush to clean visible tooth surfaces

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Toothbrush
Description: A standard size manual toothbrush to clean visible tooth surfaces

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Toothbrush
Description: A standard size manual toothbrush to clean visible tooth surfaces

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Toothbrush
Description: A standard size manual toothbrush to clean visible tooth surfaces

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interproximal Cleaning Device
Description: An electronic device that combines water and air to clean between the teeth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interproximal Cleaning Device
Description: An electronic device that combines water and air to clean between the teeth
Study: NCT01286064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Fluoroscopy
Description: Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Fluoroscopy
Description: Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
Study: NCT03103048

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Without bandages
Description: All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Without bandages
Description: All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Without bandages
Description: All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Without bandages
Description: All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: With placebo
Description: All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: With placebo
Description: All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: With placebo
Description: All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: With placebo
Description: All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: With bandage
Description: All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: With bandage
Description: All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: With bandage
Description: All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members
Study: NCT02950818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take Heart
Description: Participants receive an evidence-based heart disease self management program consisting of a combination of five two and a half hour group sessions and telephone counseling offered by a trained facilitator employed by the Detroit Area Agency on Aging. The program is designed so that participants select an area to work on (e.g., diet, exercise, medication taking, communication with health care professionals) and receive support, information, and encouragement from group members and program facilitators, to help them reach their goals.
Study: NCT01205984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a random allocation chart based on a table of random numbers. Oral AMX/C was administered 45/6.4 mg/kg/d (maximum 2000/285 mg/d) for 30 days for both groups. Oral MP was administered for the first 15 days: 1 mg/kg/d (maximum 40 mg/d) for 10 days, 0.75 mg/kg/d for 2 days, 0.5 mg/kg/d for 2 days, and 0.25 mg/kg/d for 1 day. Placebo tablets contained lactose and were of same size and color as MP tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a random allocation chart based on a table of random numbers. Oral AMX/C was administered 45/6.4 mg/kg/d (maximum 2000/285 mg/d) for 30 days for both groups. Oral MP was administered for the first 15 days: 1 mg/kg/d (maximum 40 mg/d) for 10 days, 0.75 mg/kg/d for 2 days, 0.5 mg/kg/d for 2 days, and 0.25 mg/kg/d for 1 day. Placebo tablets contained lactose and were of same size and color as MP tablets.
Study: NCT03990610

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mammoplasty
Description: Undergo standard of care breast reconstructive surgery
Study: NCT00342628

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTP
Description: DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
Study: NCT01350674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Description: endobronchial ultrasound transbronchial needle aspiration
Study: NCT03580538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistive exercise with elastic tube
Description: performed training with elastic tubing for six weeks, twice a week and the load was progressively increased every 15 days.
Study: NCT01819207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood test by thromboelastography
Study: NCT01681186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680 Capsule(s) (Reference)
Description: Administered orally as a capsule(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680 Capsule(s) (Reference)
Description: Administered orally as a capsule(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680 Tablet (Test)
Description: Administered orally as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680 Tablet (Test)
Description: Administered orally as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680 Tablet (Test)
Description: Administered orally as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Administered orally as a capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule(s)
Description: Administered orally as a capsule(s)
Study: NCT03377595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: TAP (Transversus Abdominis Plane) block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Wound infiltration
Study: NCT01000298

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: liquid placebo medication given twice per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: liquid amoxicillin given twice per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefdinir
Description: liquid cefdinir given twice per day for 7 days
Study: NCT02322580

Intervention type: DRUG
Intervention: etanercept
Study: NCT01434901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol (25 mg)
Description: 25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol (25 mg)
Description: 25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol (25 mg)
Description: 25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol (50 mg)
Description: 50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol (50 mg)
Description: 50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol (50 mg)
Description: 50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol (100 mg)
Description: 100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol (100 mg)
Description: 100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol (100 mg)
Description: 100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
Study: NCT01095081

Intervention type: DRUG
Intervention: Gadobutrol (Gadovist, BAY86-4875)
Description: Patients requiring contrast enhanced MRI using Gadovist. Administration of Gadovist at the discretion of the attending physician.
Study: NCT00559104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carmustine
Description: Unique to the Carmustine in Conditioning arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Used in Both Arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Used in Both Arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Used in Both Arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Used in Both Arms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous hematopoietic stem cell transplantation
Description: Both arms are given autologous stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous hematopoietic stem cell transplantation
Description: Both arms are given autologous stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Description: Both arms are given peripheral blood stem cell transplantation (Peripheral blood stem cells are the material, autologous transplant is the modality).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Description: Both arms are given peripheral blood stem cell transplantation (Peripheral blood stem cells are the material, autologous transplant is the modality).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total-body irradiation
Description: Unique to the Radiation in Conditioning Arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF is given in both treatment arms, both to mobilize stem cells before apheresis, and to promote recovery of granulocytes after stem-cell re-infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF is given in both treatment arms, both to mobilize stem cells before apheresis, and to promote recovery of granulocytes after stem-cell re-infusion.
Study: NCT04463563

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiological
Description: Changes to carbon dioxide, oxygen flow, cardiac output, blood pressure, haemoglobin, surgical surveillance, depth of anaesthesia, patient position.